VolitionRx Limited (VNRX)
- Previous Close
0.8290 - Open
0.8400 - Bid 0.8000 x 1200
- Ask 0.8912 x 1000
- Day's Range
0.8150 - 0.9000 - 52 Week Range
0.5500 - 1.8000 - Volume
306,311 - Avg. Volume
193,562 - Market Cap (intraday)
72.015M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5000 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.73
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
www.volition.com110
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VNRX
Performance Overview: VNRX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VNRX
Valuation Measures
Market Cap
68.03M
Enterprise Value
53.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
76.17
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-97.27%
Return on Equity (ttm)
--
Revenue (ttm)
775.3k
Net Income Avi to Common (ttm)
-35.32M
Diluted EPS (ttm)
-0.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
20.73M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.48M
Research Analysis: VNRX
Company Insights: VNRX
VNRX does not have Company Insights